```
Page 1
         IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
             BEFORE THE PATENT TRIAL AND APPEAL BOARD
3
     AMNEAL PHARMACEUTICALS, LLC,
     and AMNEAL PHARMACEUTICALS OF ) IPR2018-00608
5
     NEW YORK, LLC,
                                        ) Patent No.
                                        ) 9,161,926
6
                         Petitioners,
7
     VS.
8
     ALMIRALL, LLC,
9
                         Patent Owner. )
10
11
12
13
14
            DEPOSITION OF ALEXANDER M. KLIBANOV, PH.D.
15
                        San Diego, California
16
                      Wednesday, March 13, 2019
17
18
19
20
21
22
23
     Stenographically reported by:
24
     Tricia Rosate, RDR, RMR, CRR, CCRR
     CSR No. 10891
25
     Job No. 156070
```



Page 2	Page 3
Wednesday, March 13, 2019 8:58 a.m. DEPOSITION OF ALEXANDER M. KLIBANOV, PH.D., taken at Regus, 350 Tenth Avenue, Suite 1000, San Diego, California, commencing at 8:58 a.m. and concluding at 1:20 p.m., Wednesday, March 13, 2019, before Tricia Rosate, RDR, RMR, CRR, CCRR, CSR 10891, a Certified Shorthand Reporter.	1 A P P E A R A N C E S: 2 For the Petitioners: 3 STERNE, KESSLER, GOLDSTEIN & FOX 1100 New York Avenue 4 Washington, D.C. 20005 BY: DENNIES VARUGHESE, Pharm.D. 5 ADAM LaROCK, ESQ. 6 7 8 9 For the Patent Owner: 10 FENWICK & WEST 1191 Second Avenue 11 Seattle, Washington 98101 BY: ELIZABETH HAGAN, PH.D. 12 13 14 15 16 17 18 19 20 21 22 23 24 25
INDEX INDEX WITNESS: Alexander M. Klibanov, Ph.D. EXAMINATION PAGE By Mr. Varughese	Page 5 SAN DIEGO, CALIFORNIA; WEDNESDAY, MARCH 13, 2019 8:58 A.M 1:20 P.M. ALEXANDER M. KLIBANOV, PH.D., having been first duly sworn, testified as follows: EXAMINATION BY MR. VARUGHESE: Q. Good morning, Dr. Klibanov. A. Good morning, Mr. Varughese. Q. Can you state your name for the record, your full name. A. Alexander M. Klibanov, K-l-i-b-a-n-o-v. A. Yes. Q. About how many times? A. Quite a few times. Q. Would you say more than ten? A. Over what period of time? Q. Your career. A. Yes. Q. More than 20? A. Yes. Q. More than 30? A. I'm not sure. Q. Fair to say between 20 and 30, roughly?



Page 6 Page 7 1 A. May be fair. I don't know how accurate it is. like you and I are both two reasonable guys here today, 2 2 Q. Of those cases, how many were patent cases? 3 A. All. A. I can only speak for myself. 4 Q. How many times have you testified at trial, 4 Q. Okay. 5 5 MR. VARUGHESE: Can I get a copy of the would you say? 6 A. Over what period of time? declaration? 7 7 Q. Your career. Q. Dr. Klibanov, I'm going to mark -- or I'm going 8 8 A. I would say maybe between a dozen and two dozen to hand you what's been marked as Almirall Exhibit 2003. 9 9 A. Thank you. times. 10 10 Q. Okay. So you're generally familiar with the (Exhibit 2003 was referenced.) 11 11 BY MR. VARUGHESE: process of a deposition. I'll ask you questions. You'll 12 12 let me finish asking the questions. You'll answer the Q. Do you recognize this document? 13 13 questions. If you don't understand the questions, you'll A. It seems to be a copy of my IPR declaration 14 14 ask me for clarification? minus the exhibits and attachments. And so, before you 15 15 A. Well, I -- what you just said sort of seems continue, let me just say that there is a clerical error 16 16 inherently unfair because you said that I'll let you that I found in my declaration in preparation for my 17 17 finish your question, but you didn't say that you'll let deposition, a clerical error that unfortunately is 18 18 me finish my answer. repeated several times, for which I apologize, and I'd 19 19 Q. I didn't say I wouldn't let you finish the like to correct this clerical error for the record before 20 20 we proceed with the deposition. answer, either. 21 21 A. But if you found it necessary to say that I'll Q. Sure. Please. 22 22 let you finish your answer -- your question, then it Before you start, Dr. Klibanov, I just want to 23 seems reasonable for you to say that you'll let me finish 23 note for the record that you took out a piece of paper 24 24 my answer. that looks like you have some notes on it. I'm going to 25 25 ask that that be marked at this deposition. Q. I think that sounds reasonable. So it looks Page 8 Page 9 1 1 A. I'll be flattered. "consisting of." 2 2 Q. Okay. Please proceed. Next one on the same page, page 79, 3 3 A. So, as I said, it's basically one error, which paragraph 170, both in the first and the third lines. 4 4 unfortunately was repeated several times, and the error Instead of "comprising," it should be "consisting of." 5 5 itself is that it says "comprising"; whereas, in fact, it Next one is page 80, paragraph 171. In the 6 6 should have said "consisting of." first line, it says "comprise," which should be "consists 7 7 of" -- "consist of." In one instance, which I will specifically 8 8 denote, it's actually "comprise," which actually should And in the third line, instead of "comprising," 9 9 have been "consists of." it should be "consisting of." 10 10 And this clerical error is made in the following Next one is page 82, paragraph 176. It's the 11 11 places in my declaration. First there's page 9 -- and sixth line. Again, instead of "comprising," it should be 12 12 so, as I state them, I will also correct them in the copy "consisting of." 13 13 of the declaration that I have in front of me. The next line is -- and that's the last page 14 14 So the first one is page 9, paragraph 14, third where this clerical error has been made. It's page 91. 15 15 bullet point on that page, second line. So instead of First of all, the title of subsection 3, instead of 16 16 "comprising," "consisting of." "comprising," it should be "consisting of." 17 17 The second is page 61, paragraph 137, third Also paragraph 195, the third line, instead of 18 18 "comprising," "consisting of." bullet point, second line. Again, same clerical error, 19 19 "consisting of" should be instead of "comprising." And, finally, paragraph 196, third line, instead 20 20 Next one is -- next page is page 79 -of "comprising," again, "consisting of." 21 21 So that's all. And I apologize for this Q. Hang on. Before you move on --22 22 Thank you. Go ahead. clerical error, and I am pleased to hand over to you the

23

24

25

A. The next one is then page 79, title of the

subsection there. It's subsection 3, the second line.

Again, instead of "comprising," it should have been

23

24

25

notes that I made for myself.

MR. LaROCK: That will be AMN1051.

(Exhibit AMN1051 was marked for identification.)

Page 10 Page 11 1 BY MR. VARUGHESE: Q. And who wrote these errors in the first -- these 2 2 Q. Thank you for that, Dr. Klibanov. clerical errors in the first place? Was that you, or was 3 3 Is there any other errors that you wish to it somebody else? 4 correct in your declaration? 4 A. I'm not sure I understand the question. 5 5 A. Well, first of all, I don't view those as Q. What part don't you understand? 6 6 A. You said, "Who wrote these errors?" And it just errors. I think it's one clerical error that 7 7 unfortunately was repeated several times. doesn't make sense to me. 8 8 And, second of all, the answer to your question Q. Someone wrote the declaration; right? 9 9 A. I wrote my declaration. Yes. is no. 10 10 Q. When did you -- strike that. Q. So you typed up every word of this declaration? 11 11 I'm going to refer to it as an error. Do you A. No. I typed many words of this declaration. 12 want me to call it something else? Is it an error? 12 Some others, I dictated or explained what I want stated. 13 13 A. I would like to call it a clerical error. Q. Okay. Did anyone else type or dictate any part 14 14 Q. Okay. When did you become aware of this of this declaration? 15 15 clerical error? A. I presume that a secretary in the law firm did 16 16 A. When I started preparing for this deposition the some typing because, as I said, I only typed portions of 17 17 other day. this declaration. But whoever typed whatever portion, 18 18 Q. Do you remember which day? it's my responsibility, and that's why I sincerely 19 19 A. I believe it was -- so today is Wednesday, so apologize for that. 20 20 that was Monday. Q. And so these nine clerical errors, did you type 21 21 Q. Was it brought to your attention by an attorney or dictate those errors, or did somebody else? 22 22 or anyone else? A. There's no nine clerical errors. There is one 23 A. No. I discovered it myself, and then yesterday, 23 clerical error that was repeated several times. And I 24 24 when I was preparing for this deposition with Dr. Hagan don't remember the exact nitty-gritty of that. 2.5 25 here, I mentioned it to her. Q. Repeated nine times; correct? Page 12 Page 13 1 1 A. Well, there are nine bullet points. In some of page, but one is higher than the other; right? those places, it was actually more than once. 2 Q. Correct. 3 3 Q. So more than nine. Yes? A. Okay. 4 4 A. I mean, I just said that there are nine places Q. Yeah. 5 where -- nine pages where this clerical error is made A. So page 9? 6 6 and, in some of them, more than once. Q. Page 13. 7 Q. So more than nine instances, that clerical error A. Oh, 13. I'm sorry. 8 appears in your declaration; correct? Q. No problem. 9 9 A. Correct. So, specifically, I want to draw your attention 10 10 Q. Let's turn to page 13 of your declaration. to the remainder of paragraph 27 in your declaration. 11 11 A. Just a second. I'm looking at the bottom of the You see the very first line. There's a phrase 12 12 page, and there are two sets of numbers. There is one there. It says "wherein the composition does not 13 13 number that was actually my number that I put there, and comprise adapalene"? Do you see that? 14 then there's another one that says, for example, "7 of 14 A. Yes. 15 15 108." So when you refer to page number, what number do Q. So is this the last part of claim 1 of the '926 16 16 you refer to?

Q. Fair enough. Thanks for that. I'm going to be referring to what you called your number, which, for the record, will be the number on top.

So there are two numbers. The bottom number is what we're going to call the Bates number, and the top number is what we're going to refer to as your number. So I'll be referring to your number unless I say otherwise.

A. So, actually, they are both at the bottom of the

- patent?
- A. Yes, that is the end of claim 1 of the '926
- patent. Q. And would you agree if I were to say that that's
- the last limitation of claim 1 of the '926 patent?
- A. So where the last limitation starts with the word "wherein"?
- O. Correct.
- A. I mean, again, I'm not an attorney or a legal expert, but it seems reasonable to me.



17

18

19

20

21

22

2.3

24

25

17

18

19

20

21

22

23

24

25

Page 14

Page 15

Page 17

- Q. Okay. That last limitation -- and I'm going to repeat it for the record -- "wherein the composition does not comprise adapalene," what does that limitation mean to you?
- A. That the claim composition doesn't comprise adapalene.
- Q. So would that be adapalene and dapsone in a single formulation, that the claimed composition does not have both of those actives in a single formulation?
 - A. I'm sorry. I don't understand the question.
 - Q. What part don't you understand?

2.3

- A. The question makes no sense to me.
- Q. Well, help me help you understand. So tell me what doesn't -- what you don't understand about it.
- A. If I don't understand something, I don't know what it means. So, I mean, I can't help you because I don't know what it is that you want to ask me. It specifically says "wherein the composition does not comprise adapalene." So it means that the claim composition does not comprise adapalene. I think it's crystal clear.
- Q. So, Dr. Klibanov, I just want to be very up front with you. We have a limited amount of time for this deposition. I'm going to be asking you quite a bit of complicated questions. If you're going to simply say

you don't know to a bunch of them and we're going to use up all our time, we're going to ask the board to bring you back for a second deposition or we may call the board today.

So it's up to you. I'm not here to play any word games with you. I'm going to use plain English. If there's a part of my question you don't understand, please let me know what part of that you don't understand. Is that okay?

A. Okay. Let me say, first of all, you don't need to threaten me.

Second of all, I'm not afraid of your threats. We'll spend whatever time we have here. My objective -- since I, in contrast to you, am under oath here, my objective is to give the best -- the most precise answers I can, and we will spend whatever time we need, whether it's today or subsequently.

If I don't understand the question and the question doesn't make sense to me, I don't know how to explain to you what it is about the question that I don't understand. As I already said, it doesn't make sense to me. And I'm not playing word games with me [as said]. I'm sure you will not be playing word games with me.

Q. So, Dr. Klibanov, I wasn't making threats. I was putting you on notice, and it appears that you

Page 16

understand my notice; that, if you do waste our time

here, we will bring you back here again for a second deposition, and we will let the board decide whether you are being reasonable or not.

A. Okay. And I resent the statement that I'm wasting anybody's time. I think you are actually wasting time now by arguing about things that are not worth arguing about.

Q. So let's go back to my question.

The word "composition," do you have an understand whether that's talking about a single formulation or not?

A. It refers to what was in line 1 of claim 1, where it says "A topical pharmaceutical composition comprising:" and then it says, again, the limitation that we're discussing now "wherein the composition."

So that's that same composition that mentioned in the first line of the claim.

Q. So I'm going to ask my question again.

Does the word "composition" in claim 1, to you, mean a single formulation?

MS. HAGAN: Objection. Asked and answered. THE WITNESS: I mean, to me, the word

"composition" in this claim, and typically in general, is synonymous with the word "formulation." So we're talking about this particular -- composition of this particular

formulation.

BY MR. VARUGHESE:

Q. Okay. So let's say there's a formulation that has dapsone as the only active ingredient. Would that meet that limitation, in your opinion?

MS. HAGAN: Objection. Vague.

THE WITNESS: So it contains dapsone as the sole active pharmaceutical ingredient, and it also contains the excipients that are listed in claim 1, but it does not contain adapalene.

Is that the question?

BY MR. VARUGHESE:

Q. No.

My question was: Let's say we have a pharmaceutical formulation that has dapsone as the only active ingredient. Would that meet that limitation?

- A. But it can also contain excipients; correct?
- Q. Sure
- A. Well, as I just said, if it contains dapsone as the only active ingredient and it also contains the excipients that are listed, then it will meet this limitation because it clearly will not comprise adapalene.
 - Q. So let's say we have a formulation that has



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

